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Abstract
Background: The pathogenesis for colorectal cancer remains unresolved. A growing body of evidence suggests a
direct correlation between cyclooxygenase enzyme expression, prostaglandin E2 metabolism and neoplastic
development. Thus further understanding of the regulation of epithelial functions by prostaglandin E2 is needed.
We hypothesized that patients with colonic neoplasia have altered colonic epithelial ion transport and express
functionally different prostanoid receptor levels in this respect.
Methods: Patients referred for colonoscopy were included and grouped into patients with and without colorectal
neoplasia. Patients without endoscopic findings of neoplasia served as controls. Biopsy specimens were obtained
from normally appearing mucosa in the sigmoid part of colon. Biopsies were mounted in miniaturized modified
Ussing air-suction chambers. Indomethacin (10 μM), various stimulators and inhibitors of prostanoid receptors and
ion transport were subsequently added to the chamber solutions. Electrogenic ion transport parameters (short
circuit current and slope conductance) were recorded. Tissue pathology and tissue damage before and after
experiments was assessed by histology.
Results: Baseline short circuit current and slope conductance did not differ between the two groups. Patients with
neoplasia were significantly more sensitive to indomethacin with a decrease in short circuit current of 15.1 ± 2.6
μA·cm-2 compared to controls, who showed a decrease of 10.5 ± 2.1 μA·cm-2 (p = 0.027). Stimulation or inhibition
with theophylline, ouabain, bumetanide, forskolin or the EP receptor agonists prostaglandin E2, butaprost,
sulprostone and prostaglandin E1 (OH) did not differ significantly between the two groups. Histology was with
normal findings in both groups.
Conclusions: Epithelial electrogenic transport is more sensitive to indomethacin in normal colonic mucosa from
patients with previous or present colorectal neoplasia compared to colonic mucosa from control patients.
Stimulated epithelial electrogenic transport through individual prostanoid subtype receptors EP1, EP2, EP3, and EP4
is not significantly different between neoplasia diseased patients and controls. This indicates that increased
indomethacin-sensitive mechanisms in colonic mucosa from neoplasia diseased patients are not related to
differences in functional expression of EP receptor subtypes.
Background
Colorectal cancer (CRC) is the third most common type
of cancer and the second leading cause of death among
cancers in the Western world [1]. Therapy is usually
through surgery, which in severe cases is followed by
chemotherapy [2]. There is a need for additional medi-
cal therapy and prevention of CRC, which necessitates
further insight into the presently poorly understood
mechanisms of colorectal mucosal defence, repair and
carcinogenesis. In particular, the mechanisms and signal
pathways of pre-neoplastic colorectal epithelial cells are
of special interest as these could be target for pharma-
cotherapy in the prevention of colorectal neoplasia
(CRN) and CRC.
By their inhibitory action on the cyclooxygenase
enzyme (COX), non-steroidal anti-inflammatory drugs
(NSAIDs) are partly chemopreventive against CRC, an
effect maybe particularly due to attenuation of the
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enzyme isoform 2 (COX-2) [3-6]. This protection is
believed to be mediated, at least in part, through reduc-
tion of prostaglandin E2 (PGE2) levels [7,8], as PGE2
promotes cell growth, migration and angiogenesis and
reduce apoptosis [4]. In general, the downstream cas-
cades of the PGE2 signaling are altered (due to gene
mutations) in CRN [9-11]. These mutations may both
affect PGE2 production per se via a regulation of COX
enzymes in pro-inflammatory cells including epithelial
cells as well as the PGE2-dependent signaling pathways
in target cells, Figure 1. Whether changes in levels of
PGE2 are primary or secondary causes of CRN remains
unclear. With respect to PGE2 receptors, CRC cells and
their neighboring cells have augmented expression of
receptors EP2 and EP4, while initially the EP3 receptor
expression often is lowered [4,8,12-15], Figure 1.
PGE2 is the primary endogenous agonist for the EP
receptors and stimulates all 4 EP receptor subtypes [16].
Butaprost is a selective EP2 agonist [16]. Sulprostone is
mainly an EP3 agonist but it is also a weak agonist of
EP1 [16]. PGE1 (OH) is mainly an EP4 agonist but it is
also a weak agonist of EP3 [16].
Studies of transport mechanisms in human intestinal
epithelia in vivo require invasive bothersome proce-
dures. In order to circumvent these problems, the Modi-
fied Ussing Air-Suction (MUAS) chamber has been
developed for the study of duodenal and colonic epithe-
lia in vitro [17,18]. Fairly easily, this method enables us
to study epithelial electrogenic ion transport in human
biopsies obtained during endoscopy and has been pro-
ven useful for functional receptor studies [19].
In this study we sought to establish possible differ-
ences in functional expression/response of PGE2 EP-
receptor subtypes in colonic biopsies from CRN patients
and control subjects by the use of indomethacin, PGE2
and selective EP receptor agonists. Our findings indicate
that normally appearing colon in CRN patients, includ-
ing CRC patients, express higher COX enzyme activity
than in control patients but with no difference in the
functional expression of the four EP receptor subtypes
with respect to transepithelial ion transport.
Methods
Study population
Patients referred for colonoscopy were asked to partici-
pate. Patients agreeing were pooled into the neoplasia
group (i.e. N-patients) if they presented a history of CRN
or if CRN was macroscopically detected during colono-
scopy. Patients with no previous history or present endo-
scopic signs of CRN served as controls (i.e. C-patients).
Patients with haemorrhagic diathesis, inflammatory bowel
disease or previous sigmoid resection were excluded from
the study. A total of 63 patients were enrolled, hereof 45
C-patients and 18 N-patients. Among the C-patients the
mean age was 59 years and the fraction of men was 41%.
In the N-patients group the mean age was 55 years and
32% were men. We noted patients’ medication, body mass
index, previous illness, all signs of earlier colorectal disease
and the findings from the colonoscopy at the time of
examination. During colonoscopy, biopsy specimens were
obtained from each patient. Biopsies were pinched from
normally appearing mucosa, 30 cm orally from the anus
on retraction of the endoscope. Standard biopsy forceps
(Boston Scientific, Radial Jaw 3, outside diameter of 2.2
mm) were used. Biopsies were placed in iced Ringer-solu-
tion and immediately transferred to the laboratory for
mounting in MUAS chambers.
Ethics
The study protocol was approved by the Scientific Ethi-
cal Committee for Copenhagen (KA 97161) and Freder-
iksberg Counties (KF01-232/03) and conducted in
accordance with the Helsinki declaration. All patients
participating gave written informed consent.
Mounting of biopsies and electrical measurements
Biopsies were mounted within 30 minutes in the vali-
dated MUAS chambers [18]. Mounting was carried out
at 10 times magnification by means of a stereomicro-
scope to secure mucosa-serosal orientation and proper
fixation. The exposed tissue area was 3.4 mm2. Both
sides of the tissue were bathed in bicarbonate-Ringer
solution containing the following in mM: 140 Na+, 4 K+,
121 Cl-, 1 Ca2+, 0.5 Mg2+, 0.5 SO4
2-, 25 HCO3
-, and
oxygenated with 95% O2/5% CO2, circulated by gas-lift.
Media were further added 11 mM D-glucose at the ser-
osal side and 11 mM D-sorbitol at the mucosal side.
Temperature was maintained at 37°C by water jackets.
Short circuit current (SCC, μA·cm-2) and slope conduc-
tance (G, mS·cm-2) were recorded continuously using an
automated voltage-clamp device [17]. Correction for the
resistance in solutions was performed immediately
before each new specimen was mounted. Our technique
of fixing colonic biopsies with air-suction through a 40
μm width suction-sleeve results in fairly high slope con-
ductance most likely due to an edge-leak around the
rim of the disk aperture. Conversely, the fixing method
reduces potential edge damage of the tissue [17,18]. Pro-
blems that are related to an edge-leak may be mini-
mized, by performing an accurate solution correction
just prior to insertion of the biopsy. Thus, in compari-
son with other studies on human colonic biopsies [20]
the present technique has a high edge-leak conductance
but with reduced edge damage. Therefore, our suction
system is very sensitive to minute interferences as indi-
cated by the “noise” in the SCC signals in Figure 2.
Meanwhile, on the premises of correct solution correc-
tion and voltage clamping, the absolute values of drug-
induced differential changes in SCC should be valid and
allow quantitative comparison from tissue to tissue.
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Experiments were performed after an equilibration
period of 15 minutes. Various stimulators (forskolin or
theophylline) and inhibitors (indomethacin, bumetanide
or ouabain) of epithelial ion transport, as well as EP
receptor agonists (PGE2, PGE1-(OH), butaprost or sul-
prostone) were then added separately to the serosal
bathing solution, except for indomethacin, which was
added to both sides. Indomethacin was always added 15
minutes prior to the addition of EP receptor agonists in
order to minimize tissue prostaglandin production.
Choices of concentration for the various drugs were
based on experience from previous studies [18,21].
Bumetanide was added after EP agonist experiments on
the biopsies had been completed. Forskolin or ouabain
was added at the end of the experiment as a control of
biopsy viability.
Compounds
All drugs were purchased from Sigma (Vallensbaek
Strand, Denmark) except for bumetanide, which was a
gift from Leo Pharmaceuticals, Denmark.
Medication and co-morbidity
At the time of the examination, one patient was medi-
cated with corticosteroids, two with laxatives, three with
selective serotonin reuptake inhibitors and other three
with NSAIDs, all on a daily basis. Two N-patients had
previous resections of the transverse or ascending colon
Figure 1 The synthesis, control of tissue level and signalling pathways for PGE2 is presented. The control of tissue level of PGE2 is both
through synthesis of PGE2 by the COX enzyme in and its export from pro-inflammatory cells as well as by the removal of PGE2 from the
intercellular space by prostaglandin transporter, PGT, and the efficiency of catabolism of PGE2 by enzymes such as 15-prostaglandin
dehydrogenease. For instance, expression of the COX-2 enzyme is regulated through many pathways of which several are affected in CRC. As
examples of this, somatostatin, SS, has a dampening effect on COX-2 expression, while an autocrine pathway through an epidermal growth
factor receptor, EGFR, an EP4 receptor, and microRNA stimulation increase the expression and/or activity of the enzyme. Furthermore, the activity
in PGE2-signalling pathways may vary with the expression of the PGE2 receptor subtypes, EP1, EP2, EP3 and EP4, which is affected in CRC.
Removal of PGE2 from the extracellular compartment around target cells is by diffusion to the blood stream and uptake and degradation in
lung, liver and kidney endothelial cells. Different cellular signalling pathways for PGE2 operation are indicated in the target cell. The activity in
various short-term and long-term pathways, as indicated in the target cell, is increased with the CRN/CRC conditions and therefore affecting a
host of cell responses, including ion secretion. “Various responses” as mentioned in the figure refers to differentiation, proliferation, survival/
apoptosis, exocrine secretion, altered immune response, invasiveness/metastasis, angiogenesis. Abbreviations: AA = arachidonic acid, CBR =
carbonyl reductase - also involved in degradation of PGE2, COX1/2 = cyclooxygenase isoforms 1 and 2, EGFR = epidermal growth factor
receptor, GPCR = G protein-coupled receptors, miRNA = microRNA, MRP4 = multi-drug resistance related polypeptide 4 - example of an ABC
export pump, 15-PGDH = 15-prostaglandin dehydrogenase, PGT = prostaglandin transporter, PL = phospholipid, PLA2 = phospholipase A2, RTK =
tyrosine kinase receptor pathway, SS = somatostatin, sst3/5 = somatostatin subtype receptor 3 or 5.
Kaltoft et al. BMC Gastroenterology 2010, 10:9
http://www.biomedcentral.com/1471-230X/10/9
Page 3 of 9
for neoplasia. Results for medicated patients fell within
the range of other patients (data not shown).
Data and statistical analysis
Data are presented as mean ± SEM (number of biopsy
specimens, number of patients). Wilcoxon Rank-sum
test or unpaired t-test was used for the calculation of
the p-values, depending on the results of the normality
test and the equal variance test. P-values less than 5%
were considered significant. All statistics was done on
SigmaStat 2.03 for Windows, SPSS Inc., USA.
Histological examination
Following mounting and stimulation in the MUAS
chamber, biopsies considered for histological examina-
tion were fixed in 4% buffered paraformaldehyde. After
embedding the tissue samples in paraffin, they were cut
into 10-μm sections and stained with haematoxylin/peri-
odic acid Schiff for examination in a Leitz Ortoplan




N-patients baseline values did not differ as compared to
C-patients. The baseline SCC in the C-patients was 38.1
± 7.6 μA·cm-2 (97,36) and in N-patients 41.3 ± 15.3
μA·cm-2 (39,14), p = 0.70. Baseline G in C-patients was
91.2 ± 6.3 mS·cm-2 (94,36) compared to 90.4 ± 8.1
mS·cm-2 (39,14) in the N-patients, p = 0.78. The slope
conductance was followed through experiments to
ensure stable fixation. An annotated statement on the
relatively high conductance values is given in the “Meth-
ods” section.
Stimulation
There were no significant differences between N-
patients and C-patients in the induced SCC when
stimulating with either PGE2 (200 nM), butaprost (1.5
μM), sulprostone (1 μM), PGE1 (OH) (375 nM), theo-
phylline (400 μM) or forskolin (1 μM), Figures 3 and 4.
Half-times for the SCC stimulation were equal in the
two groups and lumped here for both N- and C-
patients: PGE2 144 ± 23 s (14,8), butaprost 221 ± 11 s
(23,15), PGE1 (OH) 191 ± 15 s (16,10), sulprostone 108
± 15 s (21,13), theophylline 139 ± 9 s (36,22), and for-
skolin 304 ± 11 s (58,30).
Inhibition
The SCC in N-patient biopsies were significantly more
sensitive to indomethacin (10 μM), p = 0.027, compared
to C-patients. There were no significant differences
between N-patients and C-patients with respect to the
inhibiting effect of bumetanide (50 μM) or ouabain (200
nM), Figure 5. Halftimes for the inhibition of SCC were
equal for N- and C-patients and lumped together: for
indomethacin 170 ± 11 s (64,36), for bumetanide 64 ± 8
s (20,12) and for ouabain 131 ± 13 s (18,12). While the
drug-elicited changes in SCC amplitude may vary
between groups of patients, the lack of difference
between N- and C-patients in response halftimes for sti-
mulation and inhibition of SCC is simply indicating that
the same mechanism is affected in the biopsies by each
individual drug.
Histological examination
Histological assessments of previously mounted biopsies
were performed for the extent of tissue pathology, edge
damage and the thickness of biopsies. The damage
found in biopsies were denoted by a severity score ran-
ging from 0 to 4; 0 being severe mucosal damage and 4
being no mucosal damage; as previously described [18].
No difference in histology was detectable for N-patients
as compared to C-patients, data not shown. In particu-
lar, no signs of inflammation or neoplasia were detected
Figure 2 Typical traces of the tissue response to inhibition with 10 μM indomethacin.
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in the biopsies from N-patients. Histological examina-
tion showed good correlation between mucosa damage
and electrical parameters. Thus, disrupted mucosal
layers were almost always non-responding to stimulation
and inhibition in the MUAS chambers. Biopsies scoring
0-1 had an average increase in SCC of 2.8 ± 2.0 μA·cm-2
(53,29) in response to stimulation with forskolin, which
was significantly less compared to an average of 20.5 ±
4.0 μA·cm-2 (56,25) in the biopsies scoring 2-4, p <
0.001.
Discussion
The present study provides evidence that electrogenic
transport is altered in histological normal appearing
colonic mucosa in CRN patients with respect to indo-
methacin-sensitive mechanisms. This finding supports
that NSAID-sensitive mechanisms are activated not only
in tumor tissue [22] but also in normal appearing tissue.
Levels of PGE2 in the para-/auto-crine milieu are ele-
vated in CRN [23-25] and the clinical benefits of redu-
cing PGE2 levels for CRC has been documented
[5,22,26-30]. Accordingly, related therapeutic strategies
are suggested [31,32]. But what are the mechanisms for
the elevated PGE2 levels in CRN and how do we explain
the effect of indomethacin in the present study?
Several enzymes and regulatory pathways control the
level of PGE2 both in colonic cells and in the intercellu-
lar environment of colonic tissue, Figure 1. In particular,
it appears that the COX-2 enzyme expression and hence
its activity is elevated in human colonic carcinogenic
cells [27,33-35]. Activation of COX-2 enzymes leads to
an immediate increase in the intracellular level of PGE2,
Figure 1. Regulation of the COX-2 expression is simul-
taneously controlled by a host of intracellular and extra-
cellular signaling pathways [35-37], Figure 1. In
addition, the extracellular concentration of PGE2 is con-
trolled by several other means. Increasing the extracellu-
lar PGE2 through prostaglandin secretion in ABC efflux
transporters, MRP4 and MOAT, is probably augmented
by elevated activity in the MRP4 transporter as found in
CRC cells, Figure 1[38]. Removal of extracellular PGE2
is partially performed by a specific prostaglandin trans-
porter, PGT, and further degradation of PGE2 is by the
enzymes 15-prostaglandin-dehydrogenase, 15-PGDH,
and carbonyl reductase, CBR, of which, both the activity
by PGT and 15-PGDH are reduced in CRC cells, Figure
1[3,38,39]. Additional support for the involvement of
altered15-PGDH enzyme activity in CRC development
was recently documented in a mouse model of 15-
PGDH -/-mouse demonstrating resistance to COX-2-
Figure 3 Theophylline and forskolin-stimulated short circuit current (SCC) in human colon endoscopic biopsies from C-patients and N-
patients is presented. Numbers in parenthesis are numbers of biopsy specimens and number of patients. Increases in SCC after stimulation
with 400 μM theophylline (C-patients: 29,18), (N-patients: 7,4) and 1 μM forskolin (C-patients: 45,23), (N-patients: 13,7).
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inhibitor celecoxib’ prevention of colon tumors [40].
Thus, the combined effects of increased synthesis and
export together with reduced elimination and degrada-
tion of extracellular PGE2 in CRC point to a maintained
higher level of PGE2 in the auto-/paracrine milieu in the
CRC colonic epithelium, Figure 1. Interestingly, indo-
methacin down-regulates the expression of some of the
ABC transporters, which are up regulated in CRC
[38,41]. Therefore several mechanisms could account for
indomethacin in regulating the bioavailability of PGE2.
In the present study we found no difference in basal
electrogenic transport values or in the response to sti-
mulation with PGE2 or EP receptor subtype specific
agonists. Thus, the observed altered expression of EP
receptor subtypes in CRC patients compared to non-
CRC subjects does not seem to be manifest in the func-
tionality of the receptors in epithelial transport. We
speculate that the observed increased sensitivity to indo-
methacin in the N-patients is due to a higher baseline
production of prostaglandins in N-patients following an
increased expression/activity of the COX-2 enzyme and
export of PGE2 [27,38] and/or a lowered removal and
degradation of PGE2, Figure 1[38,39]. This would be
consistent with the lack of differences between specific
agonists of the EP receptors as well as still explaining
the chemopreventive effect of the NSAIDs. To prove the
involvement of the isoform COX-2 as a direct link to
our findings, experiments with a specific COX-2 inhibi-
tor would be required.
Although there is no significant difference in the base-
line secretion measured as SCC between N-patients and
C-patients, the basal current is nearly three times higher
than the indomethacin-induced lowering of the current.
The significantly higher (5 to 6 μA·cm-2) differential
inhibition of the basal current by indomethacin in N-
patients compared to C-patients is not discernable as a
significant difference in the basal SCC as such. Biopsies
from N-patients had a mere non-significant (3.3 μA·cm-
2) higher value of SCC in the total basal current com-
pared to C-patients. A straight forward explanation for
this lack of significance is that the total basal current is
most likely a sum of several different electrogenic trans-
port processes including amiloride-sensitive sodium
absorption and Ca2+-induced anion secretion, not
accounted for in the indometacin-sensitive transport.
This is substantiated by a partial inhibition of the
Figure 4 EP receptor subtype agonists (PGE2, butaprost, sulprostone, and PGE1-(OH))-stimulated short circuit current (SCC) in human
colon endoscopic biopsies from C-patients and N-patients is presented. Numbers in parenthesis are numbers of biopsy specimens and
number of patients. Increases in SCC after stimulation with 200 nM PGE2 (C-patients: 8,5), (N-patients: 6,3); 1.5 μM butaprost (C-patients: 12,10),
(N-patients: 11,5); 1 μM sulprostone (C-patients: 11,7), (N-patients: 10,6) and 375 nM PGE1-(OH) (C-patients: 7,6), (N-patients: 9,4).
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current by bumetanide and an even higher inhibition of
the total current by ouabain compared to indomethacin
inhibition, Figure 5. Thus a significant difference in a
single transport type, as for indomethacin, is possibly
smeared to insignificance by its inclusion in the total
basal current with a higher variability.
Of the four employed EP receptor agonists, PGE2
induced the largest increase in SCC (i.e. electrogenic
secretion), which is not surprising as PGE2 stimulates all
four EP receptor subtypes. EP4 seems to be the receptor
subtype that is responsible for the largest proportion of
this secretion, as stimulation with PGE1 (OH) brought
about the largest increase in secretion. This fits with
findings in the human duodenum using the same
experimental technique [19]. Similar mechanisms appear
to be present in rat colon, but in contrast to rats, where
EP4 is the major mediator of the PGE2 response [21],
the human colon PGE2-induced secretion seems to be
induced by all four receptor subtypes, EP4, EP2 and
EP1/EP3, Figure 4. This underlines the notable differ-
ence of functional EP receptors in some animals as
compared to man. However, in agreement with findings
in rat colon [21], PGE2 was found to be only a partial
agonist of secretion, as forskolin almost doubled the
electrogenic secretory response of PGE2. It is not possi-
ble to make any final conclusions regarding the
observed differences between human and rat colon,
although species or regional characteristics might
explain the observed differences.
The PGE1-derivative Lubiprostone is used clinically as
a laxative. Besides its prokinetic effect, Lubiprostone is
also believed to be a chloride channel, ClC-2, opener
and now further a stimulant of EP4 receptor subtypes in
human ileum and colon epithelium chloride secretion,
dependent on a well-functioning cystic fibrosis trans-
membrane conductance regulator protein, CFTR [42], as
well as of the EP4 receptor subtype in human and rat
duodenal epithelial bicarbonate secretion [19,43]. This
information corroborates our use of PGE1(OH) as a
rather specific EP4 receptor subtype agonist and that
this receptor subtype is the major pathway for PGE2-
induced colonic anion secretion in man, Figure 4.
Conclusion
Epithelial electrogenic transport is altered in histological
normal appearing colonic mucosal biopsies from
patients with previous or present colorectal neoplastic
disease with respect to indomethacin-sensitive mechan-
isms. The mode of action for the observed effect of
indomethacin does not seem related to the functionality
of expressed prostaglandin EP receptor subtypes, EP1-4,
when compared with non-neoplastic patient tissues.
Figure 5 Indomethacin, bumetanide, and ouabain-induced inhibition of short circuit current in human colon biopsies. Inhibition of
electrogenic secretion in endoscopic mucosal biopsies from the sigmoid part of colon from C-patients and N-patients. Numbers in parenthesis
are numbers of biopsy specimens and numbers of patients. Decreases in short circuit current (SCC) after inhibition with 10 μM indomethacin (C-
patients: 43,24), (N-patients: 21,12); 50 μM bumetanide (C-patients: 12,7), (N-patients: 8,5) and 200 nM ouabain (C-patients: 10,7), (N-patients: 8,5). *
p < 0.05.
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Therefore, our results point directly to a change in the
activity of COX enzymes in the normal colonic tissue
from patients with neoplasia, although at present we
cannot differentiate between the isoform of COX
enzymes possibly being involved. To do this selective
COX-1 and COX-2 inhibitors would have to be tested.
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